Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

DOI Full Paper Access

167

Citations

36

References

2008

Year

Christian Manegold, Donald Gravenor, Donald Woytowitz, J. Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur Μ. Krieg, Cynthia G. Leichman

Journal of Clinical Oncology

Abstract

The addition of PF-3512676 to taxane plus platinum chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival. Confirmatory phase III trials are ongoing.

References

	Year	Citations

Page 1